Solid Growth Derived from Successful Product Launches and Registrations - Research Report on Volcano, Dr. Reddy's, USANA, Repligen, and Portola PR Newswire NEW YORK, November 13, 2013 NEW YORK, November 13, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Volcano Corporation (NASDAQ: VOLC), Dr. Reddy's Laboratories Limited (NYSE: RDY), USANA Health Sciences, Inc. (NYSE: USNA), Repligen Corporation (NASDAQ: RGEN), and Portola Pharmaceuticals, Inc. (NASDAQ: PTLA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Volcano Corporation Research Report On November 4, 2013, Volcano Corporation (Volcano) reported Q3 2013 financial results. In Q3 2013, the Company generated revenues of $95.8 million, up 2.3% YoY. Q3 2013 net loss was $8.5 million, or $0.15 per diluted share, compared with net income of $2.0 million, or $0.04 per diluted share, in Q3 2012. "Overall, our business experienced solid growth. Growth drivers included a seven percent increase in our U.S. IVUS revenues, due in great part to a roughly 30 percent increase in peripheral revenues versus the third quarter a year ago, as well as a 27 percent increase in combined revenues in Europe," said Scott Huennekens, President and CEO of Volcano. The Full Research Report on Volcano Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/14bf_VOLC] -- Dr. Reddy's Laboratories Limited Research Report On October 31, 2013, Dr. Reddy's Laboratories Limited (Dr. Reddy's) reported unaudited consolidated Q2 FY 2014 financial results (period ended September 30, 2013). In Q2 FY 2014, the Company achieved consolidated revenues of $537 million, up 16.7% YoY. Q2 FY 2014 EBITDA was $152 million, compared with $119 million in Q2 FY 2013. During Q2 FY 2014, Dr. Reddy's launched 19 new generic products, filed 13 new product registrations, and filed 8 DMFs (Drug Master Files) globally. The Full Research Report on Dr. Reddy's Laboratories Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ea85_RDY] -- USANA Health Sciences, Inc. Research Report On November 4, 2013, USANA Health Sciences, Inc. (USANA) announced that it is building a state-of-the-art facility in Beijing, China, worth approximately $40 million. The Company informed that the new structure will be home to world-class manufacturing and production operations, and will be the largest in all of USANA's 19 international markets. The Company expects the construction of the facility to begin in 2014 and to be operational in late 2015. The Full Research Report on USANA Health Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ee40_USNA] -- Repligen Corporation On November 7, 2013, Repligen Corporation (Repligen) reported Q3 2013 financial results. On Q3 2013, the Company's total revenue was up 24.6% YoY to $18.8 million. Q3 2013 net income was $5.9 million, or $0.18 per diluted share, compared with $1.8 million, or $0.06 per diluted share, in Q3 2012. Repligen also updated its financial guidance and now expects full-year 2013 total revenue of $67 million to $68 million, compared with the previous guidance of $65 million to $67 million. The Company confirmed that the increase in expected total revenues is due to the receipt of royalties from Bristol-Myers Squibb on its US sales of Orencia, which Repligen will no longer receive on sales made after December 31, 2013. Additionally, full-year 2013 net income is expected to be $16 million to $18 million. The Full Research Report on Repligen Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/fdda_RGEN] -- Portola Pharmaceuticals, Inc. Research Report On November 5, 2013, Portola Pharmaceuticals, Inc. (Portola) reported Q3 2013 financial results. In Q3 2013, the Company generated collaboration and license revenues of $2.8 million, up 274.8% YoY. Q3 2013 net loss attributable to common stockholders was $18.6 million, or $0.53 per diluted share, compared with $11.5 million, or $8.38 per diluted share, in Q3 2012. "We believe we have an exciting portfolio of wholly-owned product candidates. Our lead agent, betrixaban, is being developed as an anticoagulant for the prevention of fatal blood clots in acute medically ill patients. Andexanet alfa has the potential to be a first-in-class reversal agent for anticoagulated patients experiencing a fatal bleed or requiring emergency surgery. And PRT2070 is a unique oral dual kinase inhibitor being evaluated in patients with hematologic cancers, including those with genetically-defined and difficult-to-treat subtypes. With the proceeds from our recently completed follow-on equity offering, we are well positioned to advance these assets to value-creating milestones planned for 2014 and 2015, including Phase 3 APEX data for betrixaban, Biologics License Application filing for andexanet alfa, and proof-of-concept data for PRT2070," said William Lis, CEO of Portola. The Full Research Report on Portola Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/102f_PTLA] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Solid Growth Derived from Successful Product Launches and Registrations - Research Report on Volcano, Dr. Reddy's, USANA,
Press spacebar to pause and continue. Press esc to stop.